1. Amor B, Silva Santos R, Nahal R, Dougados M (1994) Predictive factors for the long term outcome of Spondyloarthropathies. J Rheumatol 21:1883–1887
2. Baraliakos X, Listing J, Brandt J et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7:R439–R444
3. Brandt J, Listing J, Haibel H et al (2005) Long-term efficacy and safety of etanercept after readministration in patientswith active ankylosing spondylitis. Rheumatology 44:342–348
4. Braun J, van den Berg R, Baraklios X et al (2011) 2010 Update of of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70(6): 896–904
5. Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187–1193